Man Group’s Opus Genetics IRD Stock Holding History

Man Group’s Portfolio IRD Stock Details IRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,900	Closed	-$79K	–	2134
2021 Q2	$79K	Buy	+14,900	New	+$74K	﹤0.01%	1871

Other funds holding IRD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Man Group's IRD Position: Q3 2021 in Review

Man Group sold out of Opus Genetics (IRD) in Q3 2021, closing a stake of 14,900 shares — an estimated $79K sold.

Man Group first reported a position in IRD in Q2 2021 and held it in 1 quarter. The position peaked at $79K in Q2 2021. 30 funds tracked by Wall St. Rank hold IRD as of Q3 2021.

Man Group reported no remaining Opus Genetics position as of Q3 2021 after selling out during the quarter.
Man Group sold 14,900 Opus Genetics shares in Q3 2021, an estimated $79K.
Man Group first reported a position in Opus Genetics in Q2 2021 and held it in 1 quarter.
Man Group's Opus Genetics position peaked at $79K in Q2 2021.
30 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2021.

Based on Man Group's 13F filing for Q3 2021, filed 15 Nov 2021.